Outlook Therapeutics grants CFO 500,000 options
The CFO of Outlook Therapeutics received 500,000 inducement stock options at a $0.63 exercise price with long-term vesting.
Rhea-AI Filing Summary
Outlook Therapeutics, Inc. (OTLK) reported that its Chief Financial Officer, Kevin Michael Lundquist, received a grant of 500,000 employee stock options on September 1, 2026. The options have an exercise price of $0.63 per share and expire on September 1, 2036. The grant was made as an inducement to his employment under Nasdaq Listing Rule 5635(c)(4) and vests 25% on September 1, 2027, with the remainder vesting in equal monthly installments over the following three years, subject to his continuous service.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 500,000 shares
Grant/Award
1 txn
Insider
Lundquist Kevin Michael
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (Right to Buy) F1 | 500,000 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 500,000 contracts (Direct)
Footnotes (1)
- F1. The option was granted by Outlook Therapeutics, Inc. (the "Issuer") as an inducement material to the Reporting Person's entry into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). 25% of the shares subject to the option shall vest on September 1, 2027, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.
Key Figures
Employee stock options granted: 500,000 options
Exercise price: $0.63 per share
Expiration date: September 1, 2036
+2 more
5 metrics
Employee stock options granted
500,000 options
Grant to CFO on September 1, 2026
Exercise price
$0.63 per share
Exercise price of the CFO’s employee stock option grant
Expiration date
September 1, 2036
Expiration of the CFO’s granted options
Vesting cliff
25% on September 1, 2027
Initial vesting of the option grant subject to continuous service
Underlying common shares
500,000 shares
Common Stock underlying the granted employee stock options
Key Terms
Employee Stock Option, Nasdaq Listing Rule 5635(c)(4), inducement, vesting
4 terms
Employee Stock Option financial
"The reporting person received an Employee Stock Option (Right to Buy)"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
Nasdaq Listing Rule 5635(c)(4) regulatory
"granted as an inducement material to the Reporting Person's entry into employment"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
inducement financial
"The option was granted ... as an inducement material to the Reporting Person's entry into employment"
Something offered to persuade someone to act a certain way, such as a payment, gift, rebate, stock award, or other benefit intended to influence decisions. Investors care because inducements can change behavior inside or around a company—affecting costs, sales practices, or management incentives—and can create conflicts of interest or trigger regulatory review. Think of it like a coupon or bonus meant to sway a choice, which can alter expected outcomes for shareholders.
vesting financial
"25% of the shares subject to the option shall vest on September 1, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transaction did OTLK report for its CFO on this Form 4?
Outlook Therapeutics reported that its CFO, Kevin Michael Lundquist, received a grant of 500,000 employee stock options on September 1, 2026, as an inducement to his employment, with an exercise price of $0.63 per share and expiration on September 1, 2036.
What are the key terms of the 500,000 stock options granted by OTLK?
The CFO’s option grant covers 500,000 shares of Common Stock at an exercise price of $0.63 per share, expiring on September 1, 2036. It was granted as an inducement to employment under Nasdaq Listing Rule 5635(c)(4).
How do the OTLK CFO’s stock options vest?
According to the disclosure, 25% of the shares subject to the option will vest on September 1, 2027. The remaining shares will vest in equal monthly installments over the following three years, subject to the CFO’s continuous service with Outlook Therapeutics.
Is the OTLK CFO’s option grant a purchase or a compensation award?
The transaction is a grant or award of an employee stock option as compensation. The Form 4 characterizes it as a grant, award, or other acquisition, with no cash purchase reported and an initial option price of $0.00 for the grant itself.
Was the OTLK CFO’s option grant made under a Rule 10b5-1 trading plan?
The Form 4 indicates no Rule 10b5-1 plan: the document-level checkbox is not marked as an affirmative 10b5-1 plan, and the footnote describes the transaction as an inducement grant, not as trades under a pre-arranged trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
